protein degradation
-
Seagen and Nurix Join Forces to Develop a New Class of Cancer Medicines
Seagen and Nurix are bringing their respective technologies together to develop a new class of cancer drugs called degrader antibody conjugates. Nurix CEO Arthur Sands says the multi-year, multi-target collaboration expands the reach of each company’s technology.
-
Astellas Strikes Another Deal to Expand in Cancer, Partnering With PeptiDream
Astellas Pharma has identified targeted protein degradation as one of the key areas for growth. The PeptiDream alliance is the latest one Astellas has struck in this particular area of drug research as it aims to find new ways to go after difficult cancer targets.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
BMS protein degradation drug research turns to a startup to find molecular glues
Bristol Myers Squibb’s drug R&D includes targeted protein degradation, an approach that can require proteins that don’t normally interact to find a way to stick together. BMS is turning to startup A-Alpha Bio to discover “molecular glues” that can accomplish the task.
-
Novartis, UC Berkeley-spawned startup snags $65M to keep key proteins out of the cell’s trash can
Vicinitas Therapeutics is developing small molecule drugs that stabilize key proteins, preventing them from going to a cell’s built-in disposal system. The startup, which stems from a research partnership between Novartis and the University of California, Berkeley, has raised $65 million in Series A funding.
-
Ambagon adds $85M for molecular glues that stick to elusive protein targets
Biotech startup Ambagon Therapeutics is taking a new approach to making elusive protein targets “druggable” by using molecular glues. The biotech has a pipeline of preclinical cancer drugs and it has raised $85 million to support their development.
-
RA Capital reveals next play in protein degradation, this time outside the cell
The first wave of biotechs developing drugs that employ targeted protein degradation target disease-causing proteins inside the cell. Biotech startup Avilar Therapeutics, formed by RA Capital Management and led by CEO Dan Grau, is targeting proteins outside of the cell and it’s out of stealth backed by $60 million.
-
Eli Lilly aims for the next-generation of protein degraders via Lycia R&D alliance
Eli Lilly is entering the field of protein-degrading drugs through a partnership with Lycia Therapeutics, a startup whose technology goes further than the first wave of such drugs. Lilly paid $35 million to begin the alliance, which spans up to five drugs.
-
Pfizer commits $1B to Arvinas for share of protein degrading breast cancer drug
Arvinas’ early clinical data for its targeted protein degradation drug for breast cancer drew partnering interest from several companies. Pfizer beat them all with a deal that pays the biotech $1 billion to share in the development and commercialization of this therapy.
-
Bristol Myers Squibb SVP Ho Sung Cho highlights legacy and ongoing research in protein degradation
Cho discusses Bristol Myers Squibb’s research efforts in the field of protein degradation to advance potential treatments for a broad range of diseases. In a recent MedCity Pivot Podcast, he also shared insights on his approach to drug discovery, perspectives on dealing with failure, and some of the work his teams are doing in the COVID-19 space.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Monte Rosa raises $96M Series B for drug development platform technology
The Boston-based company plans to develop small-molecule therapeutics that go after historically “undruggable” targets using a process known as protein degradation.
-
Arvinas raises $41.6M for protein degradation drugs
Yale spinout Arvinas just raised $41.6 million for its platform of protein degradation drugs – a different mechanism than the standard protein inhibition drugs on the market.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
